The pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA animal rule
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00014
- Awardee
-
Innovation Pathways, LLC UEI NAHEV73JLXH3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,608,865
Award facts
- Opportunity
-
- Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Bio-dosimetry Devices Pre-Solicitation · 75N93021R00019 · Posted Nov 15, 2021
- Contract value 100% obligated
- $3,608,865.00 Current and potential, with all options
- Completion date 84% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 16 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Palo Alto, CA 94301, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $109,177 | |
| Other Administrative Action | $0 | |
| Change Order | $499,908 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,499,864 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,499,916 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Innovation Pathways, LLC for the pharmacological development of IPW-5371 Fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA Animal Rule on July 1, 2023, with a ceiling value of $3,608,865.
The originating pre-solicitation, posted November 15, 2021, sought research and development of biodosimetry approaches and medical countermeasures to assess and mitigate acute or delayed radiation injuries. The procurement aims to support development of safe and effective countermeasures to reduce radiation-associated mortality and morbidity and advance biodosimetry biomarkers and devices for triage and treatment strategies in mass casualty radiation incidents. Proposals were required to demonstrate efficacy of medical countermeasures when administered at least 24 hours post-exposure or effectiveness of biodosimetry signatures within timeframes ranging from 30 minutes to 7 days, with establishment of a target product profile.
Place of performance is Palo Alto, CA 94301. The contract carries cost-plus-fixed-fee pricing and runs through June 30, 2027. This effort falls under NAICS codes 541711, 541712, or 541715 for biotechnology and life sciences research and development.
Quick answers
Who was awarded contract 75N93023C00014?
75N93023C00014 was awarded to Innovation Pathways, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2023.
How much is contract 75N93023C00014 worth?
The government has obligated $3,608,865 on 75N93023C00014.
Was contract 75N93023C00014 competed?
The extent of competition for 75N93023C00014 was full and open competition. The government received 16 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award